Recombinant T Cell Receptor Ligand Treatment Improves Neurological Outcome in the Presence of Tissue Plasminogen Activator in Experimental Ischemic Stroke

Wenbin Zhu, Nicole L. Libal, Amanda Casper, Sheetal Bodhankar, Halina Offner, Nabil Alkayed

Research output: Contribution to journalArticle

16 Citations (Scopus)

Abstract

RTL1000 is a partial human MHC molecule coupled to a human myelin peptide. We previously demonstrated that RTL1000 was protective against experimental ischemic stroke in HLA-DR2 transgenic (DR2-Tg) mice. Since thrombolysis with recombinant tissue plasminogen activator (t-PA) is a standard therapy for stroke, we determined if RTL1000 efficacy is altered when combined with t-PA in experimental stroke. Male DR2-Tg mice underwent 60 min of intraluminal middle cerebral artery occlusion (MCAO). t-PA or vehicle was infused intravenously followed by either a single or four daily subcutaneous injections of RTL1000 or vehicle. Infarct size was measured by 2, 3, 5-triphenyltetrazolium chloride staining at 24 or 96 h of reperfusion. Our data showed that t-PA alone reduced infarct size when measured at 24 h but not at 96 h after MCAO. RTL1000 alone reduced infarct size both at 24 and 96 h after MCAO. Combining RTL1000 with t-PA did not alter its ability to reduce infarct size at either 24 or 96 h after MCAO and provides additional protection in t-PA treated mice at 24 h after ischemic stroke. Taken together, RTL1000 treatment alone improves outcome and provides additional protection in t-PA-treated mice in experimental ischemic stroke.

Original languageEnglish (US)
Pages (from-to)612-617
Number of pages6
JournalTranslational Stroke Research
Volume5
Issue number5
DOIs
StatePublished - 2014

Fingerprint

Tissue Plasminogen Activator
T-Cell Antigen Receptor
Stroke
Ligands
Middle Cerebral Artery Infarction
Transgenic Mice
Therapeutics
HLA-DR2 Antigen
Subcutaneous Injections
Myelin Sheath
Reperfusion
Staining and Labeling
Peptides

Keywords

  • HLA-DR2 transgenic mice
  • Immunotherapy
  • Ischemic stroke
  • Recombinant T cell receptor ligand
  • Tissue plasminogen activator

ASJC Scopus subject areas

  • Clinical Neurology
  • Neuroscience(all)
  • Cardiology and Cardiovascular Medicine

Cite this

Recombinant T Cell Receptor Ligand Treatment Improves Neurological Outcome in the Presence of Tissue Plasminogen Activator in Experimental Ischemic Stroke. / Zhu, Wenbin; Libal, Nicole L.; Casper, Amanda; Bodhankar, Sheetal; Offner, Halina; Alkayed, Nabil.

In: Translational Stroke Research, Vol. 5, No. 5, 2014, p. 612-617.

Research output: Contribution to journalArticle

@article{b7998f0a701e421b87f2ac13431b623d,
title = "Recombinant T Cell Receptor Ligand Treatment Improves Neurological Outcome in the Presence of Tissue Plasminogen Activator in Experimental Ischemic Stroke",
abstract = "RTL1000 is a partial human MHC molecule coupled to a human myelin peptide. We previously demonstrated that RTL1000 was protective against experimental ischemic stroke in HLA-DR2 transgenic (DR2-Tg) mice. Since thrombolysis with recombinant tissue plasminogen activator (t-PA) is a standard therapy for stroke, we determined if RTL1000 efficacy is altered when combined with t-PA in experimental stroke. Male DR2-Tg mice underwent 60 min of intraluminal middle cerebral artery occlusion (MCAO). t-PA or vehicle was infused intravenously followed by either a single or four daily subcutaneous injections of RTL1000 or vehicle. Infarct size was measured by 2, 3, 5-triphenyltetrazolium chloride staining at 24 or 96 h of reperfusion. Our data showed that t-PA alone reduced infarct size when measured at 24 h but not at 96 h after MCAO. RTL1000 alone reduced infarct size both at 24 and 96 h after MCAO. Combining RTL1000 with t-PA did not alter its ability to reduce infarct size at either 24 or 96 h after MCAO and provides additional protection in t-PA treated mice at 24 h after ischemic stroke. Taken together, RTL1000 treatment alone improves outcome and provides additional protection in t-PA-treated mice in experimental ischemic stroke.",
keywords = "HLA-DR2 transgenic mice, Immunotherapy, Ischemic stroke, Recombinant T cell receptor ligand, Tissue plasminogen activator",
author = "Wenbin Zhu and Libal, {Nicole L.} and Amanda Casper and Sheetal Bodhankar and Halina Offner and Nabil Alkayed",
year = "2014",
doi = "10.1007/s12975-014-0348-8",
language = "English (US)",
volume = "5",
pages = "612--617",
journal = "Translational Stroke Research",
issn = "1868-4483",
publisher = "Springer US",
number = "5",

}

TY - JOUR

T1 - Recombinant T Cell Receptor Ligand Treatment Improves Neurological Outcome in the Presence of Tissue Plasminogen Activator in Experimental Ischemic Stroke

AU - Zhu, Wenbin

AU - Libal, Nicole L.

AU - Casper, Amanda

AU - Bodhankar, Sheetal

AU - Offner, Halina

AU - Alkayed, Nabil

PY - 2014

Y1 - 2014

N2 - RTL1000 is a partial human MHC molecule coupled to a human myelin peptide. We previously demonstrated that RTL1000 was protective against experimental ischemic stroke in HLA-DR2 transgenic (DR2-Tg) mice. Since thrombolysis with recombinant tissue plasminogen activator (t-PA) is a standard therapy for stroke, we determined if RTL1000 efficacy is altered when combined with t-PA in experimental stroke. Male DR2-Tg mice underwent 60 min of intraluminal middle cerebral artery occlusion (MCAO). t-PA or vehicle was infused intravenously followed by either a single or four daily subcutaneous injections of RTL1000 or vehicle. Infarct size was measured by 2, 3, 5-triphenyltetrazolium chloride staining at 24 or 96 h of reperfusion. Our data showed that t-PA alone reduced infarct size when measured at 24 h but not at 96 h after MCAO. RTL1000 alone reduced infarct size both at 24 and 96 h after MCAO. Combining RTL1000 with t-PA did not alter its ability to reduce infarct size at either 24 or 96 h after MCAO and provides additional protection in t-PA treated mice at 24 h after ischemic stroke. Taken together, RTL1000 treatment alone improves outcome and provides additional protection in t-PA-treated mice in experimental ischemic stroke.

AB - RTL1000 is a partial human MHC molecule coupled to a human myelin peptide. We previously demonstrated that RTL1000 was protective against experimental ischemic stroke in HLA-DR2 transgenic (DR2-Tg) mice. Since thrombolysis with recombinant tissue plasminogen activator (t-PA) is a standard therapy for stroke, we determined if RTL1000 efficacy is altered when combined with t-PA in experimental stroke. Male DR2-Tg mice underwent 60 min of intraluminal middle cerebral artery occlusion (MCAO). t-PA or vehicle was infused intravenously followed by either a single or four daily subcutaneous injections of RTL1000 or vehicle. Infarct size was measured by 2, 3, 5-triphenyltetrazolium chloride staining at 24 or 96 h of reperfusion. Our data showed that t-PA alone reduced infarct size when measured at 24 h but not at 96 h after MCAO. RTL1000 alone reduced infarct size both at 24 and 96 h after MCAO. Combining RTL1000 with t-PA did not alter its ability to reduce infarct size at either 24 or 96 h after MCAO and provides additional protection in t-PA treated mice at 24 h after ischemic stroke. Taken together, RTL1000 treatment alone improves outcome and provides additional protection in t-PA-treated mice in experimental ischemic stroke.

KW - HLA-DR2 transgenic mice

KW - Immunotherapy

KW - Ischemic stroke

KW - Recombinant T cell receptor ligand

KW - Tissue plasminogen activator

UR - http://www.scopus.com/inward/record.url?scp=84905582293&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84905582293&partnerID=8YFLogxK

U2 - 10.1007/s12975-014-0348-8

DO - 10.1007/s12975-014-0348-8

M3 - Article

VL - 5

SP - 612

EP - 617

JO - Translational Stroke Research

JF - Translational Stroke Research

SN - 1868-4483

IS - 5

ER -